Slide presentation of Medartis' half-year results 2025

2025 | Half-year results

Matthias Schupp, CEO | Dirk Kirsten, CFO Basel, 19 August 2025

Agenda

1. Opening remarks and highlights H1 2025

2. Financial review

3. Strategic direction: from head to toe

4. Outlook FY 2025

5. Upcoming corporate events

Matthias Schupp, CEO

Dirk Kirsten, CFO

Matthias Schupp, CEO

Matthias Schupp, CEO

3

Highlightes H1 2025

Matthias Schupp, CEO

4

Half-year 2025 │Key highlights

Organic revenue growth

+15.3% CER

 Total sales reached CHF 123.0 million,

including three months of sales from NeoOrtho in Brazil from May onwards

 Organic growth exceeded expectations and the upper end of guidance range

NeoOrtho integration

On plan

 NeoOrtho integration in Brazil on plan

 Back-office consolidation and new production facility in Curitiba to be concluded early 2026

KeriMedical partnership

US entry

 We secured the remaining 53% stake in KeriMedical in July

 Preparation for the market launch of the flagship product TOUCH in the USA

Guidance FY 2025

14-16% CER

 Following satisfying trend in H1, we raise our full-year organic sales guidance to 14-16%

 Unchanged high-teens core EBITDA margin despite US tariffs headwind

1 Organic growth denotes the increase in sales at constant exchange rates (CER), excluding the impact of M&A (i.e. NeoOrtho). 5